Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Cainap C, et al. Among authors: eskens fa. J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8. J Clin Oncol. 2015. PMID: 25488963 Free PMC article. Clinical Trial.
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
van Doorn L, Visser WJ, van Dorst DCH, Mirabito Colafella KM, Koolen SLW, de Mik AVE, Garrelds IM, Bovée DM, de Hoop EO, Bins S, Eskens FALM, Hoorn EJ, Jan Danser AH, Mathijssen RHJ, Versmissen J. van Doorn L, et al. Among authors: eskens falm. Br J Cancer. 2023 Jan;128(2):354-362. doi: 10.1038/s41416-022-02036-6. Epub 2022 Nov 10. Br J Cancer. 2023. PMID: 36357702 Free PMC article.
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Eskens FA, et al. J Clin Oncol. 2001 Feb 15;19(4):1167-75. doi: 10.1200/JCO.2001.19.4.1167. J Clin Oncol. 2001. PMID: 11181683 Clinical Trial.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: eskens fa. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Hoekstra R, et al. Among authors: eskens fa. J Clin Oncol. 2005 Aug 1;23(22):5188-97. doi: 10.1200/JCO.2005.05.013. J Clin Oncol. 2005. PMID: 16051960 Clinical Trial.
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.
138 results